Despite New Federal Actions, Prescription Drug Worry Hits Highest Level Since 2018

A new report from the health policy research firm KFF, says the Trump administration has renewed focus on lowering the cost of prescription drugs in the U.S., including the launch of TrumpRx.

The latest polling from KFF shows that about 4 in 10 U.S. adults (41%) say it is likely the Trump administration’s policies will lower prescription drug costs for people like them, but views generally follow party lines. Only the president’s base remains positive, with 79% of Republicans and 88% of MAGA supporters saying it is likely the administration will lower prescription drug costs, while much fewer independents (35%) and Democrats (11%) say it is likely.

But there is some agreement that the government should be playing a bigger role when it comes to regulating prescription drug costs, with at least two-thirds of Republicans, Democrats, and independents saying there is not as much government regulation as there should be in this area.

The latest KFF poll shows that despite the Trump administration’s recent actions on prescription drug costs, a majority of the public (59%) is worried about affording prescription drugs for themselves and their families, the largest share since KFF first polled this question in 2018. The shares of adults worried about their prescription costs are larger among adults in households with annual incomes less than $40,000 (67%) and those who take at least four prescription medications (64%).

Looking ahead to the 2026 midterm elections, the Democratic Party currently holds the advantage when it comes to who voters trust to address the cost of health care, including prescription drugs. Nearly 4 in 10 voters say they trust the Democratic Party to do a better job addressing the cost of prescription drugs (38%), 10 percentage points larger than the share who say they trust the Republican Party more (28%). However, reflecting frustrations with lawmakers over the rising costs, about one in four (27%) voters say they trust “neither party” to handle the issue.

 

Source Link

Recommended Articles

CMS Finalizes Major Changes To ACA Exchanges, Including Greater Access To Catastrophic Plans

Editor’s Note: Covered California is a State-Based Marketplace (SBM). For details on how these new rules will impact Covered California and other SBMs we recommend the following Princeton University linked report: (Broker rule changes appear at the bottom of the Princeton analysis.) https://shvs.org/wp-content/uploads/2025/06/SHVS_2025-Final-Marketplace-Integrity-Rule.pdf.   The Trump administration on Friday finalized a major rule reshaping the ...

Read More

Eroding ACA Enrollment Portends Higher Insurance Rates

Enrollment in the Affordable Care Act continues to erode as some customers struggle to make premium payments, with the declining numbers churning market uncertainty for insurers. In response, insurers are likely to raise rates again next year, following this year’s larger-than-typical hikes. Sign-ups were already down in January by about 1.2 million from last year’s record enrollment. For ...

Read More

White House Adds Generic Drugs To Direct-To-Consumer TrumpRx Site

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx, in a bid to expand a platform that is key to his administration’s efforts to lower prescription drug costs in the U.S. The administration is adding more than 600 generic drugs to the site, President Donald Trump said at an event ...

Read More

Supreme Court Rejects Big Pharma Appeals Challenging Negotiated Drug Prices In Medicare

The US Supreme Court on Monday rejected a series of appeals from several of the nation’s largest drugmakers challenging a program that is expected to save taxpayers and the federal government billions of dollars by requiring the companies to negotiate with Medicare on the prices for some of their most popular drugs. The court’s decision to deny ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square